Can-Fite BioPharma (CANF) EBT Margin (2015 - 2023)
Can-Fite BioPharma's (CANF) quarterly EBT Margin came in at 18384.52% in Q4 2023, up 291933.0% YoY from N/an in Q4 2022, and down 1832.1% on a QoQ basis from 951.53% in Q3 2023.
Can-Fite BioPharma (CANF) EBT Margin (2015 - 2023) Analysis & Trends
Can-Fite BioPharma (CANF) has 9 years of EBT Margin data on file, last reported at 18384.52% in Q4 2023.
- Quarterly EBT Margin rose 291933.0% year-over-year to 18384.52% in Q4 2023, while the trailing twelve-month figure through Dec 2023 was 4822.34% (down 15101.0% YoY) and the FY2025 annual result came in at 2426.67%, down 125753.0% from the prior year.
- EBT Margin fell to 18384.52% in Q4 2023, from 951.53% in the prior quarter.
- In the past five years, EBT Margin ranged from a high of 525.75% in Q1 2019 to a low of 21303.85% in Q4 2022.
- A 5-year average of 3236.36% and a median of 1369.13% in 2023 frame the typical range for EBT Margin.
- Annual changes were most pronounced in 2022 — EBT Margin plunged 1801561 bps — and 2023, when it soared 291933 bps.
- Tracing CANF's EBT Margin over 5 years: stood at 1094.79% in 2019, then slumped by 165 bps to 2898.67% in 2020, then fell by 13 bps to 3288.24% in 2021, then plunged by 548 bps to 21303.85% in 2022, then rose by 14 bps to 18384.52% in 2023.
- The last three EBT Margin figures came in at 18384.52% (Q4 2023), 951.53% (Q3 2023), and 1406.63% (Q2 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 35.71% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -528.97% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 18.33% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 13.77% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -25.06% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -2.67% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 12.09% |
| 10 | Can-Fite BioPharma | 2.76 Mn | -8.79 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | -18,384.52% |
| Sep 30, 2023 | -951.53% |
| Jun 30, 2023 | -1,406.63% |
| Mar 31, 2023 | -1,383.67% |
| Dec 31, 2022 | -21,303.85% |
| Sep 30, 2022 | -1,261.27% |
| Jun 30, 2022 | -1,014.71% |
| Mar 31, 2022 | -1,156.10% |
| Dec 31, 2021 | -3,288.24% |
| Sep 30, 2021 | -1,354.58% |
| Jun 30, 2021 | -1,253.20% |
| Mar 31, 2021 | -1,466.89% |
| Dec 31, 2020 | -2,898.67% |
| Sep 30, 2020 | -1,220.38% |
| Jun 30, 2020 | -1,877.94% |
| Mar 31, 2020 | -2,159.60% |
| Dec 31, 2019 | -1,094.79% |
| Sep 30, 2019 | -194.88% |
| Jun 30, 2019 | -1,581.49% |
| Mar 31, 2019 | 525.75% |